2′,4′-dihydroxychalcone, a flavonoid isolated from Herba oxytropis, suppresses PC-3 human prostate cancer cell growth by induction of apoptosis

Natural products are a promising source for the development of novel cancer therapies, due to their potential effectiveness and low toxicity proles. As a main component of Herba oxytropis , 2',4'-dihydroxychalcone (TFC) is known to demonstrate anti-tumor activity in vitro . In the present study, TFC was found to potently inhibit proliferation and induce apoptosis in PC-3 human prostate cancer cells in a dose-dependent manner. The results demonstrated that the induction of apoptosis is associated with cell cycle arrest at the G0/G1 phase and activation of caspase-3/-7. Additional mechanistic studies of two biomarkers, phosphatase and tensin homolog (PTEN) and cyclin-dependent kinase inhibitor 1B (p27 Kip1 ), in prostate cancer revealed that TFC treatment significantly upregulated the expression of PTEN and p27 Kip1 . The findings of the present study indicate that TFC-induced apoptosis in PC-3 cells via upregulation of PTEN and p27 Kip1 , which results in cell cycle arrest in G0/G1 phase, activation of caspase-3/-7 and induction of apoptosis. Therefore, TFC may be a potential compound for human prostate cancer therapy.